[HTML][HTML] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
…, E Wolin, A Hendifar, J Yao, B Chasen… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options. …
progression during first-line somatostatin analogue therapy have limited therapeutic options. …
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
…, N Puebla-Osorio, MCJ Ma, P Strati, B Chasen… - Nature medicine, 2020 - nature.com
Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than …
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than …
[HTML][HTML] Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the phase III NETTER-1 trial
J Strosberg, E Wolin, B Chasen, M Kulke… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality
of life (QoL). We assessed the impact of 177 Lu-Dotatate treatment on time to deterioration …
of life (QoL). We assessed the impact of 177 Lu-Dotatate treatment on time to deterioration …
[HTML][HTML] Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients
…, P Nagarajan, CA Torres-Cabala, BA Chasen… - … for immunotherapy of …, 2018 - Springer
Background Immune checkpoint therapy has dramatically changed the landscape of cancer
therapy, providing an efficacious and durable therapeutic option for patients with advanced-…
therapy, providing an efficacious and durable therapeutic option for patients with advanced-…
[HTML][HTML] Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine …
C Jimenez, W Erwin, B Chasen - Cancers, 2019 - mdpi.com
Low-specific-activity iodine-131–radiolabeled metaiodobenzylguanidine (I-131-MIBG) was
introduced last century as a potential systemic therapy for patients with malignant …
introduced last century as a potential systemic therapy for patients with malignant …
NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated …
JR Strosberg, EM Wolin, B Chasen, MH Kulke… - 2016 - ascopubs.org
194 Background: Currently, there are limited therapeutic options for patients with advanced
midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy. …
midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy. …
The prognostic value of interim positron emission tomography scan in patients with classical H odgkin lymphoma
Y Oki, H Chuang, B Chasen, A Jessop… - British journal of …, 2014 - Wiley Online Library
The prognostic value of interim positron emission tomography ( PET ) was evaluated after 2
cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical H odgkin …
cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical H odgkin …
[HTML][HTML] Early survival prediction framework in CD19-specific CAR-T cell immunotherapy using a quantitative systems pharmacology model
Simple Summary Treatment with chimeric antigen receptor (CAR)-T cells has improved the
prognosis of patients with non-Hodgkin lymphoma (NHL) substantially. Yet, as up to 60% of …
prognosis of patients with non-Hodgkin lymphoma (NHL) substantially. Yet, as up to 60% of …
Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
…, D Tripathy, B Lim, BA Chasen - Cancer …, 2020 - Wiley Online Library
Background Radium‐223 dichloride (Ra‐223) is a targeted alpha therapy that induces
localized cytotoxicity in bone metastases. We evaluated the efficacy and safety of Ra‐223 plus …
localized cytotoxicity in bone metastases. We evaluated the efficacy and safety of Ra‐223 plus …
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high …
JR Strosberg, EM Wolin, BA Chasen, MH Kulke… - 2018 - ascopubs.org
4099 Background: The final per-protocol statistical analysis (cut–off date 24 July 2015) of PFS,
the primary endpoint of the NETTER-1 study, showed a significant difference (p < 0.0001) …
the primary endpoint of the NETTER-1 study, showed a significant difference (p < 0.0001) …